LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: Inflammatory resolution versus thrombotic chaos

Annals of the New York Academy of Sciences

Volumn 1254, Issue 1, 2012, Pages 18-32

  Badimon, Lina ^a,b   Vilahur, Gemma ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherothrombosis; High density lipoproteins; Low density lipoproteins

Indexed keywords

ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR;

APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HEMOSTASIS; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; THROMBOSIS;

EID: 84859836292     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06480.x     Document Type: Article

References (103)

1. Wilson, P.W. et al 1998. Prediction of coronary heart disease using risk factor categories. Circulation. 97: 1837-1847.
2. Keys, A. 1980. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease.
3. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285: 2486-2497.
4. Hackam, D.G. & S.S. Anand 2003. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 290: 932-940.
5. Yusuf, S. et al 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 364: 937-952.
6. Kullo, I.J. & C.M. Ballantyne 2005. Conditional risk factors for atherosclerosis. Mayo Clin. Proc. 80: 219-230.
7. Assmann, G. et al 2005. Implications of emerging risk factors for therapeutic intervention. Nutr. Metab. Cardiovasc. Dis. 15: 373-381.
8. Badimon, L., G. Vilahur & T. Padro 2009. Lipoproteins, platelets and atherothrombosis. Rev. Esp. Cardiol. 62: 1161-1178.
9. Badimon, L., R.F. Storey & G. Vilahur 2011. Update on lipids, inflammation and atherothrombosis. Thromb. Haemost. 105(Suppl 1): S34-S42.
10. Badimon, L. et al 2006. Cell biology and lipoproteins in atherosclerosis. Curr. Mol. Med. 6: 439-456.
11. Vidal, F. et al 1998. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. Eur. J. Biochem. 252: 378-384.
12. Tabas, I., K.J. Williams & J. Boren 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 116: 1832-1844.
13. Flood, C. et al 2004. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler. Thromb. Vasc. Biol. 24: 564-570.
14. Llorente-Cortes, V. et al 2002. Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism. Circulation. 106: 3104-3110.
15. Guyton, J.R., K.F. Klemp & M.P. Mims 1991. Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. J. Lipid Res. 32: 953-962.
16. Llorente-Cortes, V. & L. Badimon 2005. LDL receptor-related protein and the vascular wall: implications for atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 25: 497-504.
17. Llorente-Cortes, V., J. Martinez-Gonzalez & L. Badimon 2000. LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 20: 1572-1579.
18. Boucher, P. et al 2003. LRP: role in vascular wall integrity and protection from atherosclerosis. Science. 300: 329-332.
19. Llorente-Cortes, V. et al 2007. Adipocyte differentiation-related protein is induced by LRP1-mediated aggregated LDL internalization in human vascular smooth muscle cells and macrophages. J. Lipid. Res. 48: 2133-2140.
20. Llorente-Cortes, V. et al 2007. Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. Cardiovasc. Res. 74: 526-536.
21. Llorente-Cortes, V. et al 2004. Intracellular lipid accumulation, low-density lipoprotein receptor-related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries. Eur. J. Clin. Invest. 34: 182-190.
22. Yla-Herttuala, S. 1999. Oxidized LDL and atherogenesis. Ann. N. Y. Acad. Sci. 874: 134-137.
23. Svensson, L. et al 2002. Inhibitory effects of N-acetylcysteine on scavenger receptor class A expression in human macrophages. J. Intern. Med. 251: 437-446.
24. Kamada, N., T. Kodama & H. Suzuki 2001. Macrophage scavenger receptor (SR-A I/II) deficiency reduced diet-induced atherosclerosis in C57BL/6J mice. J. Atheroscler. Thromb. 8: 1-6.
25. Murase, T. et al 2000. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler. Thromb. Vasc. Biol. 20: 715-720.
26. Doran, A.C., N. Meller & C.A. McNamara 2008. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28: 812-819.
27. Padro, T. et al 2008. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc. Res. 77: 211-220.
28. Garcia-Arguinzonis, M. et al Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 30: 1212-1219.
29. Fernandez-Ortiz, A. et al 1994. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J. Am. Coll. Cardiol. 23: 1562-1569.
30. Badimon, J.J. et al 1999. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 99: 1780-1787.
31. Camino-Lopez, S. et al 2007. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. Cardiovasc. Res. 73: 208-216.
32. Llorente-Cortes, V. et al 2004. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation. 110: 452-459.
33. Downs, J.R. et al 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279: 1615-1622.
34. Cannon, C.P. et al 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350: 1495-1504.
35. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360: 7-22.
36. Pedersen, T.R. et al 2005. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 294: 2437-2445.
37. LaRosa, J.C. et al 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352: 1425-1435.
38. Nissen, S.E. et al 2006. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 295: 1556-1565.
39. Nicholls, S.J. et al Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 365: 2078-2087.
40. Badimon, J.J., C.G. Santos-Gallego & L. Badimon [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]. Rev. Esp. Cardiol. 63(Suppl 2): 20-35.
41. Assmann, G. et al 1996. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 124(Suppl): S11-20.
42. Goldbourt, U., S. Yaari & J.H. Medalie 1997. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler. Thromb. Vasc. Biol. 17: 107-113.
43. Gordon, D.J. et al 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
44. Gordon, T. et al 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62: 707-714.
45. 1979. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee. Circulation. 60: 427-439.
46. 1984. Lipid Research Clinics Program. JAMA. 252: 2545-2548.
47. 1982. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 248: 1465-1477.
48. Olsson, A.G. et al 2005. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur. Heart. J. 26: 890-896.
49. Nicholls, S.J. et al 2007. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 297: 499-508.
50. Ibanez, B., G. Vilahur & J.J. Badimon 2007. Plaque progression and regression in atherothrombosis. J. Thromb. Haemost. 5(Suppl 1): 292-299.
51. Choi, B.G. et al 2006. The role of high-density lipoprotein cholesterol in atherothrombosis. Mt. Sinai. J. Med. 73: 690-701.
52. Singh, V. et al Low high-density lipoprotein cholesterol: current status and future strategies for management. Vasc. Health. Risk. Manag. 6: 979-996.
53. Liu, L. et al 2003. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J Biol. Chem. 278: 42976-42984.
54. Williams, D.L. et al 1999. Scavenger receptor BI and cholesterol trafficking. Curr. Opin. Lipidol. 10: 329-339.
55. Fu, X. et al 2001. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378-38387.
56. Malerod, L. et al 2002. Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem. Biophys. Res. Commun. 299: 916-923.
57. Venkateswaran, A. et al 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. U S A. 97: 12097-12102.
58. Trigatti, B.L., M. Krieger & A. Rigotti 2003. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23: 1732-1738.
59. Goldstein, J.L. & M.S. Brown 1987. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation. 76: 504-507.
60. Badimon, J.J. et al 1989. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab. Invest. 60: 455-461.
61. Taylor, A.J., H.J. Lee & L.E. Sullenberger 2006. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 22: 2243-2250.
62. Nissen, S.E. et al 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
63. Ibanez, B. et al 2008. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J. Am. Coll. Cardiol. 51: 1104-1109.
64. Cimmino, G. et al 2009. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). J. Cell. Mol. Med. 13: 3226-3235.
65. Ibanez, B. et al 2012. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 220: 72-77.
66. Cimmino, G. et al 2009. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I. J. Cell. Mol. Med. 13: 3226-3235.
67. Navab, M. et al 2001. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21: 481-488.
68. Aviram, M. et al 2000. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 101: 2510-2517.
69. Shih, D.M. et al 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
70. Tward, A. et al 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 106: 484-490.
71. Leviev, I. et al 2002. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis. 161: 463-467.
72. Mackness, B. et al 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107: 2775-2779.
73. Assmann, G. & A.M. Gotto, Jr. 2004. HDL cholesterol and protective factors in atherosclerosis. Circulation. 109: III8-14.
74. Barter, P.J., P.W. Baker & K.A. Rye 2002. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. Opin. Lipidol. 13: 285-288.
75. Cockerill, G.W. et al 2001. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 103: 108-112.
76. Clay, M.A. et al 2001. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis. 157: 23-29.
77. Spieker, L.E. et al 2002. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 105: 1399-1402.
78. Bisoendial, R.J. et al 2003. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 107: 2944-2948.
79. Rodriguez, C. et al 2009. Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost. 101: 665-673.
80. Yuhanna, I.S. et al 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7: 853-857.
81. Gonzalez-Diez, M. et al 2008. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb. Haemost. 100: 119-126.
82. Vinals, M. et al 1997. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler. Thromb. Vasc. Biol. 17: 3481-3488.
83. Vinals, M., J. Martinez-Gonzalez & L. Badimon 1999. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler. Thromb. Vasc. Biol. 19: 2405-2411.
84. Nofer, J.R. et al 1996. High density lipoproteins enhance the Na+/H+ antiport in human platelets. Thromb. Haemost. 75: 635-641.
85. Aviram, M. et al 1985. Plasma lipoproteins affect platelet malondialdehyde and thromboxane B2 production. Biochem. Med. 34: 29-36.
86. Mehta, J.L. & L.Y. Chen 1996. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J. Lab. Clin. Med. 127: 287-295.
87. Korporaal, S.J. & J.W. Akkerman 2006. Platelet activation by low density lipoprotein and high density lipoprotein. Pathophysiol. Haemost. Thromb. 35: 270-280.
88. Li, D. et al 1999. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Biol. 19: 378-383.
89. Pirich, C. et al 1997. Hyperalphalipoproteinemia and prostaglandin I2 stability. Thromb. Res. 88: 41-49.
90. Escudero, I. et al 2003. Experimental and interventional dietary study in humans on the role of HDL fatty acid composition in PGI2 release and Cox-2 expression by VSMC. Eur. J. Clin. Invest. 33: 779-786.
91. Naqvi, T.Z. et al 1999. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am. J. Cardiol. 84: 1011-1017.
92. Griffin, J.H. et al 1999. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 103: 219-227.
93. Epand, R.M. et al 1994. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler. Thromb. 14: 1775-1783.
94. Lesnik, P. et al 1993. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler. Thromb. 13: 1066-1075.
95. Saku, K. et al 1985. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb. Res. 39: 1-8.
96. Nofer, J.R. et al 2001. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276: 34480-34485.
97. Besler, C. et al High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr. Pharm. Des. 16: 1480-1493.
98. Norata, G.D. et al Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 220: 11-21.
99. Choi, B.G. et al 2006. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr. Mol. Med. 6: 571-587.
100. Barter, P.J. et al 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
101. Blasi, E. et al 2009. Effects of CP-532, 623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J. Cardiovasc. Pharmacol. 53: 507-516.
102. Barter, P. 2009. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am. J. Cardiol. 104: 10E-15E.
103. Van Lenten, B.J. et al 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.